

# Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

NCT05422222

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Vertex Pharmaceuticals Incorporated
Enrollment	210 participants

## Key Eligibility Criteria

---

### Inclusion (1)

- Participants with stable CF and at least 1 TCR mutation (including F508del) in the CFTR gene

### Exclusion (3)

- History of solid organ, hematological transplantation, or cancer
- Hepatic cirrhosis with portal hypertension, moderate hepatic impairment (Child Pugh Score 7 to 9), or severe hepatic impairment (Child Pugh Score 10 to 15)
- Lung infection with organisms associated with a more rapid decline in pulmonary status

## Locations (38 total)

---

Children's Hospital of Orange County, Orange, California, United States  
Stanford University Clinical and Translational Research Unit, Palo Alto, California, United States  
Children's Hospital of Colorado, Aurora, Colorado, United States  
... and 35 more locations